No Evidence of Lantus-Cancer Link
One of the hottest topics at the American Diabetes Association's 72nd annual Scientific Sessions was new data on insulin glargine (Lantus) and cancer. In 2009, an analysis of a German health database suggested that insulin glargine—a long-acting insulin analog—increased the risk of cancer. That prompted scientists to examine three similar health databases in the United States and northern Europe. Their results, presented at the meeting, showed no evidence of an increased risk of cancer among users of insulin glargine. However, database analyses can't be conclusive. So, in a separate study, researchers tracked more than 12,000 people in 40 countries with type 2 diabetes or prediabetes. Half took insulin glargine daily while the rest did not. After an average of six years, glargine users were no more likely to have developed cancer than nonusers.
Source: The New England Journal of Medicine, June 11, 2012